{
  "id": "5c8973f3d558e5f232000007",
  "type": "factoid",
  "question": "Which was the first gene therapy to receive marketing authorization in the European Union?",
  "ideal_answer": "The first gene therapy to receive marketing authorization in the European Union was Glybera (alipogene tiparvovec).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28284702"
  ],
  "snippets": [
    {
      "text": "Alipogene tiparvovec (Glybera\u00ae) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase Deficiency), a 15-year registry focusing on LPLD was launched in 2014 as part of its Risk Management Plan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28284702",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Glybera, Alipogene tiparvovec"
}